The Munich medtech startup Reactive Robotics wants to become the leading player in AI- and robot-assisted mobilization in hospitals, geriatrics, and care. Investors such as Dr. Doll, TQ-Group, Henrik Schunk, Stephan Huber, and the EIC Fund share the vision and are providing Reactive Robotics with five million euros for its continued growth. In 2023, the company already received 2.5 million euros in funding for its R&D activities from the European Innovation Council.
Reactive Robotics: driving market launch nationally and internationally
With the new funding, the Munich startup aims to further develop its AI-supported robotic assistance system Vemotion for patients and care workers, therapists, and physicians, and to strategically continue its market launch nationally and internationally.
With its assistive robotics, critically ill and intensive care patients can be deliberately mobilized early, which is crucial for faster recovery. It is also intended to physically relieve care and therapy staff when working with patients weighing up to 180 kg and to create new opportunities with “colleague Vemotion” despite limited staffing.
Brigitte Schrätzenstaller, CEO of Reactive Robotics, is delighted about the current investment:
“We are thrilled by the trust our investors are placing in us. This funding round is a significant step for Reactive Robotics and enables us to realize our vision of improved and efficient patient care and relief for staff.”
“A promising player in medical robotics”
Maximilian Große-Dunker, CEO and COO, emphasizes:
“With additional funds, we will consistently pursue our data strategy and internationalization.”
And investor Dr. Theo Doll adds:
“We firmly believe in the potential of Reactive Robotics to revolutionize the healthcare industry. The combination of innovative technology and the dedicated team makes the company a promising player in medical robotics.”
